Confo Therapeutics Raises €30m Series A To Drug Difficult Targets
Executive Summary
Belgian drug discovery company raises funds to finance development of its platform to discover compounds targeting difficult-to-drug GPCRs and advance lead program to the clinic.
You may also be interested in...
Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try
Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Need a specific report? 1000+ reports available
Buy Reports